It is essential to ensure the safety profiles of potential COVID-19 therapies are supported by robust data so that healthcare providers and physicians can make appropriate, evidence-based decisions, writes Dr. Andrew Rut.
Dr. Andrew Rut
Advertisement
Articles by Dr. Andrew Rut
Advertisement
Latest Updated Articles
- What is Required of Drug Safety During the COVID-19 Pandemic
Published: April 9th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Brent Saunders: Eyeing New Horizons
2
TrumpRX Has a Blind Spot and It Can Redefine Patient Access
3
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial
4
FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies
5
